[ad_1]
NEW YORK (Reuters) – A U.S. choose on Wednesday dismissed a lawsuit accusing Bristol Myers (NYSE:) Squibb Co of defrauding traders who stood to obtain $6.4 billion had it received federal approval by specified deadlines for medicine developed by the previous Celgene Corp (NASDAQ:).
[ad_2]
Source link
TERADAT SANTIVIVUT No person can predict if the cycle of acrimonious recriminations between Israel and Iran will cease this week – after the Iranian retaliation for the destroyed...
Read more
Richelieu {Hardware} Ltd. (RCH), a number one distributor of specialty {hardware} and complementary merchandise, maintained steady gross sales within the first quarter of 2024, matching the earlier 12...
Read more
filo Article Goal Historic outcomes are among the many first issues many traders take into account when analyzing ETFs. Aside from contrarians, traders seek for funds with strong...
Read more
By Aatreyee Dasgupta (Reuters) -U.S. Metal shareholders on Friday authorised its proposed $14.9 billion acquisition by Japan's Nippon Metal, as anticipated, taking the merger one step nearer to...
Read more
Annually, B-Inventory facilitates the motion of billions of {dollars} value of returned and overstock stock through the world’s largest B2B recommerce market. This implies, in fact, that we...
Read more
